Secukinumab, a human monoclonal antibody that binds to IL-17A, is already used clinically to treat arthritis-associated symptoms and joint disease damage in ankylosing spondylitis and psoriatic arthritis, further supporting the antagonistic role of IL-17A in joint disease [184]. Here, IL17A is linked to ankylosing spondylitis.